PL375559A1 - Calcium receptor modulating agents - Google Patents
Calcium receptor modulating agentsInfo
- Publication number
- PL375559A1 PL375559A1 PL03375559A PL37555903A PL375559A1 PL 375559 A1 PL375559 A1 PL 375559A1 PL 03375559 A PL03375559 A PL 03375559A PL 37555903 A PL37555903 A PL 37555903A PL 375559 A1 PL375559 A1 PL 375559A1
- Authority
- PL
- Poland
- Prior art keywords
- modulating agents
- calcium receptor
- receptor modulating
- calcium
- agents
- Prior art date
Links
- 102000013830 Calcium-Sensing Receptors Human genes 0.000 title 1
- 108010050543 Calcium-Sensing Receptors Proteins 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/22—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of calcitonin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/86—Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38327002P | 2002-05-23 | 2002-05-23 | |
| US10/444,945 US7176322B2 (en) | 2002-05-23 | 2003-05-22 | Calcium receptor modulating agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL375559A1 true PL375559A1 (en) | 2005-11-28 |
Family
ID=29586996
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL03375559A PL375559A1 (en) | 2002-05-23 | 2003-05-23 | Calcium receptor modulating agents |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7176322B2 (https=) |
| EP (1) | EP1509518B1 (https=) |
| JP (1) | JP4642461B2 (https=) |
| AR (1) | AR040095A1 (https=) |
| AT (1) | ATE544762T1 (https=) |
| AU (1) | AU2003237235B2 (https=) |
| CA (1) | CA2485685C (https=) |
| ES (1) | ES2378759T3 (https=) |
| MX (1) | MXPA04011469A (https=) |
| PL (1) | PL375559A1 (https=) |
| TW (1) | TW200410960A (https=) |
| WO (1) | WO2003099814A1 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6908935B2 (en) * | 2002-05-23 | 2005-06-21 | Amgen Inc. | Calcium receptor modulating agents |
| WO2005065050A2 (ja) * | 2003-12-25 | 2005-07-21 | Asahi Kasei Pharma Corporation | ２環化合物 |
| GB0400781D0 (en) * | 2004-01-14 | 2004-02-18 | Novartis Ag | Organic compounds |
| US8362274B2 (en) | 2004-05-28 | 2013-01-29 | Mitsubishi Tanabe Pharma Corporation | Arylalkylamine compound and process for preparing the same |
| US7361789B1 (en) | 2004-07-28 | 2008-04-22 | Amgen Inc. | Dihydronaphthalene compounds, compositions, uses thereof, and methods for synthesis |
| WO2006123725A1 (ja) | 2005-05-19 | 2006-11-23 | Astellas Pharma Inc. | ピロリジン誘導体またはその塩 |
| ES2400693T3 (es) * | 2005-09-02 | 2013-04-11 | Amgen Inc. | Regulación del equilibrio de fluido intestinal usando calcimiméticos |
| WO2007100880A1 (en) * | 2006-02-28 | 2007-09-07 | Amgen Inc. | Cinnoline and quinazoline derivates as phosphodiesterase 10 inhibitors |
| JP5309014B2 (ja) * | 2006-03-23 | 2013-10-09 | アムジエン・インコーポレーテツド | シナカルセットの多形体の製造および使用のための方法および組成物 |
| CN101437490A (zh) * | 2006-04-20 | 2009-05-20 | 安美基公司 | 稳定乳液配方 |
| CA2681582C (en) | 2007-03-30 | 2015-07-14 | Amgen Inc. | Methods of treating bowel disorders |
| EP2212284B1 (en) * | 2007-10-15 | 2014-04-30 | Amgen Inc. | Calcium receptor modulating agents |
| EP2303890A4 (en) * | 2008-06-19 | 2012-04-11 | Progenics Pharm Inc | INHIBITORS OF PHOSPHATIDYLINOSITE-3-KINASE |
| WO2010104882A1 (en) | 2009-03-10 | 2010-09-16 | Amgen Inc. | Methods of modulating sperm motility |
| WO2010136037A1 (en) | 2009-05-27 | 2010-12-02 | Leo Pharma A/S | Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof |
| JP2012528084A (ja) | 2009-05-27 | 2012-11-12 | レオ ファーマ アクティーゼルスカブ | 新規のカルシウム感知受容体調節化合物およびその医薬用途 |
| EP2588445A1 (en) | 2010-06-30 | 2013-05-08 | Leo Pharma A/S | New polymorphic form of a calcimimetic compound |
| WO2012000499A1 (en) | 2010-06-30 | 2012-01-05 | Leo Pharma A/S | New polymorphic form of a calcimimetic compound |
| CN103270018A (zh) | 2010-11-26 | 2013-08-28 | 利奥制药有限公司 | 钙敏感受体激活化合物 |
| WO2012069402A1 (en) | 2010-11-26 | 2012-05-31 | Leo Pharma A/S | Substituted cyclopentyl - azines as casr- active compounds |
| JP2014507375A (ja) | 2010-11-26 | 2014-03-27 | レオ ファーマ アクティーゼルスカブ | カルシウム感知受容体活性化合物 |
| CN103228619A (zh) | 2010-11-26 | 2013-07-31 | 利奥制药有限公司 | 钙传感受体活性化合物 |
| WO2014033604A1 (en) * | 2012-08-27 | 2014-03-06 | Lupin Limited | Arylalkylamine compounds as calcium sensing receptor modulators |
| GB201217330D0 (en) | 2012-09-28 | 2012-11-14 | Univ Cardiff | Therapeutic for treating inflammatory lung disorders |
| CN105120863B (zh) * | 2013-03-14 | 2021-06-04 | 奥斯特克有限公司 | 促进骨生长的烷基胺骆驼蓬碱衍生物 |
| CA3108714A1 (en) | 2018-08-14 | 2020-02-20 | Osteoqc Inc. | Pyrrolo - dipyridine compounds |
| CA3109104A1 (en) | 2018-08-14 | 2020-02-20 | Osteoqc Inc. | Fluoro .beta.-carboline compounds |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US143212A (en) * | 1873-09-23 | Improvement in attachments for ladies work-tables | ||
| US444946A (en) * | 1891-01-20 | Method of electric welding | ||
| PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
| CN1192011C (zh) | 1991-08-23 | 2005-03-09 | Nps药物有限公司 | 对钙受体具活性的芳烷基胺化合物 |
| US6001884A (en) | 1991-08-23 | 1999-12-14 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
| RU2147574C1 (ru) | 1991-08-23 | 2000-04-20 | Эн-Пи-Эс Фармасьютикалз, Инк. | Арилалкиламины, композиции, способы лечения и диагностики, способы идентификации соединения |
| US6011068A (en) | 1991-08-23 | 2000-01-04 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
| US6031003A (en) | 1991-08-23 | 2000-02-29 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
| EP0637237B1 (en) | 1993-02-23 | 2004-05-19 | Brigham And Women's Hospital, Inc. | Calcium receptor-active molecules |
| AU3414295A (en) | 1994-08-19 | 1996-03-14 | Nps Pharmaceuticals, Inc. | Methods and compounds active at metabotropic glutamate receptors useful for treatment of neurological disorders and diseases |
| AU3642795A (en) | 1994-09-27 | 1996-04-19 | Merck & Co., Inc. | Endothelin receptor antagonists for the treatment of emesis |
| US6211244B1 (en) * | 1994-10-21 | 2001-04-03 | Nps Pharmaceuticals, Inc. | Calcium receptor-active compounds |
| US5585388A (en) | 1995-04-07 | 1996-12-17 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acetylcholine receptors |
| DE69637587D1 (de) | 1995-07-26 | 2008-08-21 | Astrazeneca Ab | Chimäre rezeptoren und verfahren zur identifizieren verbindungen mit einem aktivität als metabotropischen glutamatrezeptoren sowie verwendung solcher verbindungen in der behandlung von neurologischer erkrankungen und neurologischenstörrungen |
| DE69733649T2 (de) | 1996-04-09 | 2006-05-18 | NPS Pharmaceuticals, Inc., Salt Lake City | Calcylitische verbindungen |
| EP0907631B1 (en) * | 1996-05-01 | 2003-06-18 | Nps Pharmaceuticals, Inc. | Inorganic ion receptor-active compounds |
| US6362231B1 (en) | 1996-07-08 | 2002-03-26 | Nps Pharmaceuticals, Inc. | Calcium receptor active compounds |
| TR199902012T2 (xx) | 1997-02-21 | 2000-01-21 | Bayer Aktiengesellschaft | Arils�lfonamidler ve analoglar� |
| UY24949A1 (es) | 1997-04-08 | 2001-04-30 | Smithkline Beecham Corp | Compuestos calcilíticos |
| WO1999001439A1 (en) | 1997-07-03 | 1999-01-14 | Du Pont Pharmaceuticals Company | Aryl-and arylamino-substituted heterocycles as corticotropin releasing hormone antagonists |
| WO2000009491A1 (en) | 1998-08-12 | 2000-02-24 | Smithkline Beecham Corporation | Calcilytic compounds |
| AU760889B2 (en) | 1998-10-14 | 2003-05-22 | Ortho-Mcneil Pharmaceutical, Inc. | 1,2-disubstituted cyclopropanes |
| SI1157005T1 (en) | 1999-02-24 | 2005-02-28 | F. Hoffmann-La Roche Ag | 3-phenylpyridine derivatives and their use as nk-1 receptor antagonists |
| HRP20010603A2 (en) | 1999-02-24 | 2002-08-31 | Hoffmann La Roche | Phenyl-and pyridinyl derivatives |
| EP1074539B1 (en) | 1999-08-04 | 2007-10-17 | Sumitomo Chemical Company, Limited | Process for producing optically active 3,3,3,-trifluoro-2-hydroxy-2-methylpropionic acid, and salt thereof |
| FR2800735B1 (fr) | 1999-11-09 | 2002-02-01 | Centre Nat Rech Scient | Nouvelles aralkyle-1,2-diamines possedant une activite calcimimetique et leur mode de preparation |
| EP1116711B1 (de) | 1999-12-18 | 2005-12-14 | Wella Aktiengesellschaft | 2-Aminoalkyl-1,4-diaminobenzol-Derivate und diese Verbindungen enthaltende Färbemittel |
| FR2809396B1 (fr) | 2000-05-24 | 2005-10-14 | Centre Nat Rech Scient | Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation |
| DE10028402A1 (de) | 2000-06-13 | 2001-12-20 | Merck Patent Gmbh | Pyridin-2-yl-aminoalkycarbonylglycyl-beta-alanin und Derivate |
| UY26780A1 (es) | 2000-06-15 | 2002-01-31 | Pharmacia Corp | Cicloalquil avb3 antagonistas |
| WO2002051805A1 (de) | 2000-12-27 | 2002-07-04 | Bayer Aktiengesellschaft | Indol-derivate |
| CA2448160A1 (en) * | 2001-05-25 | 2002-12-05 | Queen's University At Kingston | Heterocyclic beta-amino acids and their use as anti-epileptogenic agents |
-
2003
- 2003-05-22 US US10/444,945 patent/US7176322B2/en not_active Expired - Lifetime
- 2003-05-23 MX MXPA04011469A patent/MXPA04011469A/es active IP Right Grant
- 2003-05-23 ES ES03736701T patent/ES2378759T3/es not_active Expired - Lifetime
- 2003-05-23 EP EP03736701A patent/EP1509518B1/en not_active Expired - Lifetime
- 2003-05-23 WO PCT/US2003/016384 patent/WO2003099814A1/en not_active Ceased
- 2003-05-23 JP JP2004507471A patent/JP4642461B2/ja not_active Expired - Fee Related
- 2003-05-23 AR ARP030101798A patent/AR040095A1/es unknown
- 2003-05-23 PL PL03375559A patent/PL375559A1/xx not_active Application Discontinuation
- 2003-05-23 CA CA002485685A patent/CA2485685C/en not_active Expired - Fee Related
- 2003-05-23 AT AT03736701T patent/ATE544762T1/de active
- 2003-05-23 AU AU2003237235A patent/AU2003237235B2/en not_active Ceased
- 2003-05-23 TW TW092114032A patent/TW200410960A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US7176322B2 (en) | 2007-02-13 |
| TW200410960A (en) | 2004-07-01 |
| AU2003237235A1 (en) | 2003-12-12 |
| MXPA04011469A (es) | 2005-02-14 |
| EP1509518A1 (en) | 2005-03-02 |
| JP4642461B2 (ja) | 2011-03-02 |
| EP1509518B1 (en) | 2012-02-08 |
| US20040077619A1 (en) | 2004-04-22 |
| CA2485685A1 (en) | 2003-12-04 |
| AU2003237235B2 (en) | 2007-08-23 |
| CA2485685C (en) | 2010-02-02 |
| AR040095A1 (es) | 2005-03-16 |
| ATE544762T1 (de) | 2012-02-15 |
| JP2005530811A (ja) | 2005-10-13 |
| ES2378759T3 (es) | 2012-04-17 |
| WO2003099814A1 (en) | 2003-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL375559A1 (en) | Calcium receptor modulating agents | |
| PL376438A1 (en) | Calcium receptor modulating arylalkylamines | |
| PL382706A1 (pl) | Związek modulujący receptor wapnia i jego zastosowanie | |
| GB2384570B (en) | Modulators | |
| AU2003290778A8 (en) | Non-steroidal farnesoid x receptor modulators | |
| AU2002353403A8 (en) | Oxo or oxy-pyridine compounds as 5-ht4 receptor modulators | |
| EP1585745A4 (en) | COMPOUNDS AND COMPOSITIONS FOR FC RECEPTOR MODULATION | |
| EP1556053A4 (en) | ANTI-INFLAMMATORY AGENTS | |
| EP1553075A4 (en) | LPA Receptor Antagonists | |
| AU149713S (en) | Two tone dog bone | |
| IL159594A0 (en) | Adenosine a3 receptor modulators | |
| PL372804A1 (en) | Vibrator | |
| AU2003295355A8 (en) | Anchor | |
| AU2003206264A8 (en) | Modulating tolerance by modulating fcgammariib receptor signalling | |
| IL166069A0 (en) | CCK-1 receptor modulators | |
| EP1581309A4 (en) | KINASE MODULATORS | |
| AU2003290818A8 (en) | Topoisomerase-targeting agents | |
| EP1490509A4 (en) | MODULATION OF INSULIN RECEPTOR SIGNAL TRANSMISSION | |
| IL164169A0 (en) | Non-steroidal progesterone receptor modulators | |
| AU2003288576A8 (en) | Rabeprazole calcium | |
| GB0215389D0 (en) | Receptor | |
| AU2003300867A8 (en) | Uses of the snorf207 receptor | |
| GB0212954D0 (en) | Paving | |
| GB0223394D0 (en) | Anchorage systmes | |
| GB0200373D0 (en) | Compressible Fill |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |